Melatonin use for SARS-CoV-2 infection: Time to diversify the treatment portfolio
- Autores
- Reiter, Russel; Sharma, Ramaswamy; Tan, Dun Xian; Neel, Richard L.; Simko, Fedor; Manucha, Walter Ariel Fernando; Rosales Corral, Sergio; Cardinali, Daniel Pedro
- Año de publicación
- 2022
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- No single treatment will eliminate the COVID-19 pandemic. It is imperative that all available tactics and medications be used to overcome this disease, although it will probably never totally disappear. Melatonin is a very inexpensive molecule so it is affordable in all areas of the world, it does not require refrigeration and it has a very long shelf-life. Melatonin has no substantial side effects even at extremely high doses, no overdose has ever been achieved, and it can be self-administered via several routes. Considering its efficacy in both experimental studies and clinical trials, the portfolio of medications used to a curtail a COVID-19 infection should clearly include melatonin. Since melatonin inhibits many types of viruses, it should also be considered a potential treatment of Ebola, Zeka, and hantavirus infections.
Fil: Reiter, Russel. University Of Texas At San Antonio. University Of Texas Health Science Center At San Antonio (ut Health San Antonio); Estados Unidos
Fil: Sharma, Ramaswamy. University Of Texas At San Antonio. University Of Texas Health Science Center At San Antonio (ut Health San Antonio); Estados Unidos
Fil: Tan, Dun Xian. University Of Texas At San Antonio. University Of Texas Health Science Center At San Antonio (ut Health San Antonio); Estados Unidos
Fil: Neel, Richard L.. University Of Texas At San Antonio. University Of Texas Health Science Center At San Antonio (ut Health San Antonio); Estados Unidos
Fil: Simko, Fedor. Universidad Nacional de Cuyo; Argentina
Fil: Manucha, Walter Ariel Fernando. Universidad Nacional de Cuyo; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza; Argentina
Fil: Rosales Corral, Sergio. Instituto Mexicano del Seguro Social; México
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina - Materia
-
MELATININ
COVID-19
TREATMENT
PREVENTION - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
.jpg)
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/163088
Ver los metadatos del registro completo
| id |
CONICETDig_fc060b469494bb1d758ad5a5de8bfc6e |
|---|---|
| oai_identifier_str |
oai:ri.conicet.gov.ar:11336/163088 |
| network_acronym_str |
CONICETDig |
| repository_id_str |
3498 |
| network_name_str |
CONICET Digital (CONICET) |
| spelling |
Melatonin use for SARS-CoV-2 infection: Time to diversify the treatment portfolioReiter, RusselSharma, RamaswamyTan, Dun XianNeel, Richard L.Simko, FedorManucha, Walter Ariel FernandoRosales Corral, SergioCardinali, Daniel PedroMELATININCOVID-19TREATMENTPREVENTIONhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3No single treatment will eliminate the COVID-19 pandemic. It is imperative that all available tactics and medications be used to overcome this disease, although it will probably never totally disappear. Melatonin is a very inexpensive molecule so it is affordable in all areas of the world, it does not require refrigeration and it has a very long shelf-life. Melatonin has no substantial side effects even at extremely high doses, no overdose has ever been achieved, and it can be self-administered via several routes. Considering its efficacy in both experimental studies and clinical trials, the portfolio of medications used to a curtail a COVID-19 infection should clearly include melatonin. Since melatonin inhibits many types of viruses, it should also be considered a potential treatment of Ebola, Zeka, and hantavirus infections.Fil: Reiter, Russel. University Of Texas At San Antonio. University Of Texas Health Science Center At San Antonio (ut Health San Antonio); Estados UnidosFil: Sharma, Ramaswamy. University Of Texas At San Antonio. University Of Texas Health Science Center At San Antonio (ut Health San Antonio); Estados UnidosFil: Tan, Dun Xian. University Of Texas At San Antonio. University Of Texas Health Science Center At San Antonio (ut Health San Antonio); Estados UnidosFil: Neel, Richard L.. University Of Texas At San Antonio. University Of Texas Health Science Center At San Antonio (ut Health San Antonio); Estados UnidosFil: Simko, Fedor. Universidad Nacional de Cuyo; ArgentinaFil: Manucha, Walter Ariel Fernando. Universidad Nacional de Cuyo; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza; ArgentinaFil: Rosales Corral, Sergio. Instituto Mexicano del Seguro Social; MéxicoFil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaWiley-liss, div John Wiley & Sons Inc.2022-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/163088Reiter, Russel; Sharma, Ramaswamy; Tan, Dun Xian; Neel, Richard L.; Simko, Fedor; et al.; Melatonin use for SARS-CoV-2 infection: Time to diversify the treatment portfolio; Wiley-liss, div John Wiley & Sons Inc.; Journal of Medical Virology; 94; 7; 7-2022; 2928-29300146-6615CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1002/jmv.27740info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1002/jmv.27740info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-11-12T09:43:00Zoai:ri.conicet.gov.ar:11336/163088instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-11-12 09:43:01.054CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
| dc.title.none.fl_str_mv |
Melatonin use for SARS-CoV-2 infection: Time to diversify the treatment portfolio |
| title |
Melatonin use for SARS-CoV-2 infection: Time to diversify the treatment portfolio |
| spellingShingle |
Melatonin use for SARS-CoV-2 infection: Time to diversify the treatment portfolio Reiter, Russel MELATININ COVID-19 TREATMENT PREVENTION |
| title_short |
Melatonin use for SARS-CoV-2 infection: Time to diversify the treatment portfolio |
| title_full |
Melatonin use for SARS-CoV-2 infection: Time to diversify the treatment portfolio |
| title_fullStr |
Melatonin use for SARS-CoV-2 infection: Time to diversify the treatment portfolio |
| title_full_unstemmed |
Melatonin use for SARS-CoV-2 infection: Time to diversify the treatment portfolio |
| title_sort |
Melatonin use for SARS-CoV-2 infection: Time to diversify the treatment portfolio |
| dc.creator.none.fl_str_mv |
Reiter, Russel Sharma, Ramaswamy Tan, Dun Xian Neel, Richard L. Simko, Fedor Manucha, Walter Ariel Fernando Rosales Corral, Sergio Cardinali, Daniel Pedro |
| author |
Reiter, Russel |
| author_facet |
Reiter, Russel Sharma, Ramaswamy Tan, Dun Xian Neel, Richard L. Simko, Fedor Manucha, Walter Ariel Fernando Rosales Corral, Sergio Cardinali, Daniel Pedro |
| author_role |
author |
| author2 |
Sharma, Ramaswamy Tan, Dun Xian Neel, Richard L. Simko, Fedor Manucha, Walter Ariel Fernando Rosales Corral, Sergio Cardinali, Daniel Pedro |
| author2_role |
author author author author author author author |
| dc.subject.none.fl_str_mv |
MELATININ COVID-19 TREATMENT PREVENTION |
| topic |
MELATININ COVID-19 TREATMENT PREVENTION |
| purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3 |
| dc.description.none.fl_txt_mv |
No single treatment will eliminate the COVID-19 pandemic. It is imperative that all available tactics and medications be used to overcome this disease, although it will probably never totally disappear. Melatonin is a very inexpensive molecule so it is affordable in all areas of the world, it does not require refrigeration and it has a very long shelf-life. Melatonin has no substantial side effects even at extremely high doses, no overdose has ever been achieved, and it can be self-administered via several routes. Considering its efficacy in both experimental studies and clinical trials, the portfolio of medications used to a curtail a COVID-19 infection should clearly include melatonin. Since melatonin inhibits many types of viruses, it should also be considered a potential treatment of Ebola, Zeka, and hantavirus infections. Fil: Reiter, Russel. University Of Texas At San Antonio. University Of Texas Health Science Center At San Antonio (ut Health San Antonio); Estados Unidos Fil: Sharma, Ramaswamy. University Of Texas At San Antonio. University Of Texas Health Science Center At San Antonio (ut Health San Antonio); Estados Unidos Fil: Tan, Dun Xian. University Of Texas At San Antonio. University Of Texas Health Science Center At San Antonio (ut Health San Antonio); Estados Unidos Fil: Neel, Richard L.. University Of Texas At San Antonio. University Of Texas Health Science Center At San Antonio (ut Health San Antonio); Estados Unidos Fil: Simko, Fedor. Universidad Nacional de Cuyo; Argentina Fil: Manucha, Walter Ariel Fernando. Universidad Nacional de Cuyo; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza; Argentina Fil: Rosales Corral, Sergio. Instituto Mexicano del Seguro Social; México Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina |
| description |
No single treatment will eliminate the COVID-19 pandemic. It is imperative that all available tactics and medications be used to overcome this disease, although it will probably never totally disappear. Melatonin is a very inexpensive molecule so it is affordable in all areas of the world, it does not require refrigeration and it has a very long shelf-life. Melatonin has no substantial side effects even at extremely high doses, no overdose has ever been achieved, and it can be self-administered via several routes. Considering its efficacy in both experimental studies and clinical trials, the portfolio of medications used to a curtail a COVID-19 infection should clearly include melatonin. Since melatonin inhibits many types of viruses, it should also be considered a potential treatment of Ebola, Zeka, and hantavirus infections. |
| publishDate |
2022 |
| dc.date.none.fl_str_mv |
2022-07 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/163088 Reiter, Russel; Sharma, Ramaswamy; Tan, Dun Xian; Neel, Richard L.; Simko, Fedor; et al.; Melatonin use for SARS-CoV-2 infection: Time to diversify the treatment portfolio; Wiley-liss, div John Wiley & Sons Inc.; Journal of Medical Virology; 94; 7; 7-2022; 2928-2930 0146-6615 CONICET Digital CONICET |
| url |
http://hdl.handle.net/11336/163088 |
| identifier_str_mv |
Reiter, Russel; Sharma, Ramaswamy; Tan, Dun Xian; Neel, Richard L.; Simko, Fedor; et al.; Melatonin use for SARS-CoV-2 infection: Time to diversify the treatment portfolio; Wiley-liss, div John Wiley & Sons Inc.; Journal of Medical Virology; 94; 7; 7-2022; 2928-2930 0146-6615 CONICET Digital CONICET |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.1002/jmv.27740 info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1002/jmv.27740 |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Wiley-liss, div John Wiley & Sons Inc. |
| publisher.none.fl_str_mv |
Wiley-liss, div John Wiley & Sons Inc. |
| dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
| reponame_str |
CONICET Digital (CONICET) |
| collection |
CONICET Digital (CONICET) |
| instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
| _version_ |
1848597681167925248 |
| score |
12.976206 |